Clinical Characteristics of Non-B and Non-C Biopsy-Proven Primary Liver Cancers in an HBV- Endemic Area: A Retrospective Study
Zhen Hu,Huaying Zhou
DOI: https://doi.org/10.2147/jhc.s455741
2024-04-25
Journal of Hepatocellular Carcinoma
Abstract:Zhen Hu, Huaying Zhou Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China Correspondence: Huaying Zhou, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, People's Republic of China, Email Objective: To explore the distribution of probable causes and clinical characteristics of non-B and non-C (NBNC) primary liver cancer (PLC) patients in the HBV-endemic region. Methods: A total of 86 individuals with biopsy-proven NBNC-PLC were enrolled. NBNC-PLC patients were defined as negative for both anti-HCV antibodies and five serum hepatitis B markers. Patients' characteristics were collected from medical records. Results: Among them, most of the NBNC-PLC patients had intrahepatic cholangiocarcinoma (ICC) (81.4%), and 12.8% had hepatocellular carcinoma (HCC). The NBNC ICC group had more platelet count, GGT, and CA199 levels; approximately two-thirds were female, and it was more often present in patients with biliary inflammatory diseases, especially intrahepatic biliary lithiasis. The NBNC HCC group was older and had a higher proportion of dyslipidemia, obesity, cirrhosis, and AFP levels. Conclusion: Our data revealed that most of the NBNC PLC patients were ICC. Female patients with biliary inflammatory diseases and higher CA199 levels had an increased risk of ICC, and patients with metabolic risk factors and elevated AFP levels were more likely to develop HCC. Additional research should be performed to verify this finding. Keywords: non-B, non-C, primary liver cancers, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, retrospective study Over the past few decades, there has been a marked increase in both the incidence and mortality of liver cancer. Primary liver malignancies are expected to become the second most common cause of cancer-related deaths in the United States by 2030. 1 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, which accounts for about 80–90% of cases. 2 Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent primary liver cancer, accounting for 10–15% of the cases. Hepatocellular carcinoma (HCC) is a classic example of a virus-related tumor. 3 The geographical distribution of the hyper-endemic region of HCC coincides with that of chronic hepatitis B and C. 4 As the implementation of neonatal HBV vaccination programmes and treatments for viral hepatitis become more available, HBV and HCV's impact on the development of HCC is diminishing. Furthermore, it is widely recognized that it has a significant correlation with one's lifestyle, metabolic factors (diabetes and obesity), and lifestyle factors (alcohol intake and smoking) have been linked to an increased risk of HCC. 5–7 ICC arises near the segmental biliary channels. Most ICCs occur spontaneously and lack a discernible risk factor. Common risk factors for the development of ICC include chronic hepatitis and cirrhosis, infections caused by hepatobiliary flukes, biliary inflammatory diseases, primary biliary cholangitis, primary sclerosing cholangitis, cholelithiasis, bile duct adenoma, biliary papillomatosis, inflammatory bowel disease, drugs and toxins (Thorotrast), and others. 8–11 In the present study, we explored the distribution of probable etiology and clinical characteristics of non-B and non-C (NBNC) primary liver cancer patients in the HBV-endemic region, with particular focus on biopsy-proven primary liver cancers. This retrospective study was approved by the Second Xiangya Hospital of Central South University Ethics Committee. The requirement of informed consent was waived due to the retrospective nature of the study, the data was anonymized, and the absence of any risk. We retrospectively gathered data from 1854 patients newly diagnosed with primary liver cancers from January 2015 to December 2021 at the Second Xiangya Hospitals, Central South University. A total of 1224 patients (66.0%) had PLC with positive hepatitis B markers (HBsAg or HBcAb), Of these, 204 patients (11.0%) also had positive anti-HCV antibodies, and 22 patients (1.2%) had both positive HBsAg and positive anti-HCV antibodies. 426 (22.9%) patients had NBNC PLC (hepatitis B markers—all negative and anti-HCV-negative) (Figure 1). Of the 426 individuals with NBNC PLC, 340 patients had either no liver pathological examination or Incomplete information. 86 were biopsy-diagnosed non-B, non-C (NBNC)-PLC, and the patients' medical records were analyzed and assessed in the present study (Figure 2). We collected detailed information on NBNC PLC patients defined as negative for both five serum hepatitis B markers (anti -Abstract Truncated-
oncology